



TargED Biopharmaceuticals strengthens its Management Team with Key Appointments

May 2nd, 2023

Utrecht, the Netherlands

TargED Biopharmaceuticals, a leading biotechnology company dedicated to the development of innovative therapies for rare diseases, is pleased to announce the appointment of Dr. Josefin-Beate (Josi) Holz as Clinical Advisor and Gerben van 't Klooster as Chief Development Officer (CDO), effective May 1st, 2023.

Josi Holz, MD has over 25 years of experience in pharmaceutical drug development in Europe and North America. In executive managerial positions at international pharmaceutical and biotechnology companies and as clinical advisor, she has successfully advanced novel therapeutics into clinical development and lead clinical programs towards commercialization. Josi will support TargED in the role of chief medical officer (CMO).

"I am excited to join TargED Biopharmaceuticals and work with such a talented team dedicated to developing innovative treatments for patients suffering from Thrombosis in aTTP and Stroke," said Dr. Josi Holz. "I look forward to provide my extensive clinical development expertise helping the company bring new treatments to those in need."

Gerben van 't Klooster, PhD is a seasoned pharmaceutical executive with over 30 years of experience in drug development and commercialization. He joins TargED from Galapagos, where he most recently served as the Senior Vice President, Alliance Management after heading Galapagos' early development portfolio for many years. Gerben held multiple senior positions in international pharmaceutical and biotech companies Kiadis, Tibotec and Janssen Pharmaceutica. As CDO, Gerben will be responsible for leading the company's development strategy and ensuring the successful execution of all development programs.

"I am thrilled to be joining TargED at such an exciting time in the company's growth," said Gerben van 't Klooster. "I am looking forward to working with the team to advance the development of our pipeline of innovative therapies and bring hope to patients with rare diseases."

Kristof Vercruyse, CEO of TargED Biopharmaceuticals, expressed his delight in the appointments of Josi and Gerben, and looks forward to their contributions. *"We are thrilled to welcome Josi and Gerben to our team at TargED Biopharmaceuticals. Both bring a wealth of experience and expertise that will be invaluable to our efforts to develop our innovative therapy for patients suffering from Thrombosis."* said Vercruyse.



TARGED

TARGETED ENZYME DELIVERY

About TargED Biopharmaceuticals

TargED Biopharmaceuticals B.V. is a biotechnology company and spin-off of the University Medical Center Utrecht, that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. The lead compound is Microlyse, which is currently under development for thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

Contact: info@targedbio.com